- Home
- NVGS vs CVAC Comparison
NVGS vs CVAC Comparison
Compare NVGS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | CVAC |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United Kingdom | Germany |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVGS | CVAC |
|---|---|---|
| Price | $17.18 | $4.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $21.50 | $6.83 |
| AVG Volume (30 Days) | 279.9K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-24-2025 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | 33.99 | ★ 94.02 |
| EPS | ★ 1.50 | 0.94 |
| Revenue | ★ $578,158,000.00 | $83,000,117.00 |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | N/A | $23.71 |
| P/E Ratio | $11.46 | ★ $4.59 |
| Revenue Growth | ★ 2.46 | N/A |
| 52 Week Low | $10.55 | $2.48 |
| 52 Week High | $18.29 | $5.72 |
Technical Indicators
Market Signals| Indicator | NVGS | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 31.39 |
| Support Level | $17.19 | $4.00 |
| Resistance Level | $17.47 | $4.36 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 10.53 | 22.51 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.